Antiplatelet drugs, such as aspirin, P2Y12 antagonists, and glycoprotein (GP) IIb/IIIa
inhibitors, have proved to be successful in reducing the morbidity and mortality associated …

Ibrutinib is an irreversible inhibitor of Bruton's tyrosine kinase (Btk) that has proven to be an
effective therapeutic agent for multiple B‐cell‐mediated lymphoproliferative disorders …

Non-alcoholic fatty liver disease ranges from steatosis to non-alcoholic steatohepatitis
(NASH), potentially progressing to cirrhosis and hepatocellular carcinoma (HCC). Here, we …

Increasing evidence suggests that platelets play a predominant role in colon and breast
cancer metastasis, but the underlying molecular mechanisms remain elusive. Glycoprotein …

Hemostasis requires the tightly regulated interaction of the coagulation system, platelets,
other blood cells and components of the vessel wall at a site of vascular injury. The …

Abstract The glycoprotein VI (GPVI)-Fc receptor γ (FcRγ) chain is the major platelet signaling
receptor for collagen. Paradoxically, in a FeCl3 injury model, occlusion, but not initiation of …

Fibrin, the coagulation end product, consolidates the platelet plug at sites of vascular injury
and supports the recruitment of circulating platelets. In addition to integrin αIIbβ3, another as …

Platelets interact with the coagulation system in a multitude of ways, not only during the
phases of thrombus formation, but also in specific areas within a formed thrombus. This …

Platelet adhesion, activation and aggregation on the exposed subendothelial extracellular
matrix (ECM) are essential for haemostasis, but may also lead to occlusion of diseased …

Glycoprotein VI, a major platelet activation receptor for collagen and fibrin, is considered a
particularly promising, safe antithrombotic target. In this study, we show that human …